Dr. Rod Monroy is the CSO at XenoTherapeutics supporting the company’s efforts through his experience as a senior executive in managing translational research programs for cell-based biotherapeutics, immunotherapy, transplantation and regenerative medicine.


His experience ranges from hematopoietic stem cell, mesenchymal stromal cell and hepatocyte cellular therapies to xenogeneic organ transplantation.


He has been involved in all phases of biotech development from start-up to completion of Phase III studies. His background includes understanding the regulatory requirements (GLP, GMP, GCP, ICH) for FDA and clinical trials (Phase II and III).


In his over twenty years of experience in biotech, he has held senior management positions at BioTransplant, Eligix, Osiris and Cytonet.